Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle...
Data support potential for SAT-3247 in multiple degenerative muscle diseases On track to initiate first-in-human clinical trial mid-2024 for Duchenne muscular dystrophy Satellos Bioscience Inc...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of...
- Company disclosed drug target for Duchenne program; remains on track to initiate clinical trials mid-2024 - Satellos appointed Michael Cross, PhD, MBA, as Chief Business Officer and other key...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of...
The drug target for the Duchenne program is AAK1, a protein kinase in the Notch pathway, which the Company discovered can be modulated to enable muscle regeneration Satellos is conducting...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of...
NEW YORK, June 24, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the June 23rd Life...
TORONTO, June 20, 2022 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (TSXV: MSCL) (“Satellos” or the “Corporation”), a regenerative medicine company aimed at developing therapeutics that change...
TORONTO, March 09, 2022 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (TSX-V: MSCL) (“Satellos” or the “Company”), a regenerative medicine company aimed at developing therapeutics that change the...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.56 | 0.56 | 0.56 | 0 | 0 | CS |
| 4 | 0 | 0 | 0.56 | 0.56 | 0.56 | 0 | 0 | CS |
| 12 | 0 | 0 | 0.56 | 0.56 | 0.56 | 0 | 0 | CS |
| 26 | 0 | 0 | 0.56 | 0.56 | 0.56 | 0 | 0 | CS |
| 52 | 0.115 | 25.8426966292 | 0.445 | 0.61 | 0.41 | 12287 | 0.50909855 | CS |
| 156 | -0.52 | -48.1481481481 | 1.08 | 1.2 | 0.215 | 39288 | 0.49793377 | CS |
| 260 | -1.94 | -77.6 | 2.5 | 2.5 | 0.215 | 40798 | 0.63300643 | CS |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
